rosuvastatin sold brand name crestor among others statin medication used prevent cardiovascular disease high risk treat abnormal recommended used together dietary changes exercise weight taken orally common side effects include abdominal pain nausea headaches muscle serious side effects may include rhabdomyolysis liver problems use pregnancy may harm like statins rosuvastatin works inhibiting hmgcoa reductase enzyme found liver plays role producing rosuvastatin patented approved medical use united states available generic seventeenth commonly prescribed medication united states million primary use rosuvastatin prevention cardiovascular disease high risk treatment abnormal effects rosuvastatin lowdensity lipoprotein ldl cholesterol doserelated higher doses efficacious improving lipid profile patients hypercholesterolemia milligramequivalent doses atorvastatin milligramequivalent higher doses simvastatin metaanalysis showed rosuvastatin able modestly increase levels highdensity lipoprotein hdl cholesterol well cochrane review determined good evidence rosuvastatin lowering nonhdl levels linearly side effects following rare side effects serious like statins rosuvastatin possibly cause myopathy allergic reactions rosuvastatin multiple contraindications including hypersensitivity rosuvastatin component formulation active liver disease elevation serum transaminases pregnancy rosuvastatin prescribed used pregnant cause serious harm case breastfeeding unknown whether rosuvastatin passed risk myopathy may increased asian americans asians appear process drug differently half standard dose cholesterollowering benefit patients though full dose could increase risk sideeffects study drugs manufacturer astrazeneca therefore lowest dose recommended statins concern rhabdomyolysis severe undesired side effect us food drug administration fda indicated appear risk rhabdomyolysis greater crestor marketed statins mandated warning sideeffect well kidney toxicity warning added product statins increase risk consistent fdas review reported increase investigatorreported diabetes mellitus rosuvastatintreated following drugs negative interactions rosuvastatin discussed prescribing rosuvastatin structural similarities statins eg atorvastatin cerivastatin pitavastatin unlike statins rosuvastatin contains sulfur sulfonyl functional group crestor calcium salt rosuvastatin ie rosuvastatin calcium replaces hydrogen carboxylic acid group right skeletal formula top right pagecitation needed rosuvastatin competitive inhibitor enzyme hmgcoa reductase mechanism action similar putative beneficial effects rosuvastatin therapy chronic heart failure may negated increases collagen turnover markers well reduction plasma coenzyme levels patients chronic heart doserelated magnitude rosuvastatin blood lipids determined cochrane systematic review dose range mgday strong linear effects found total cholesterol reduced ldl cholesterol nonhdl cholesterol triglycerides absolute bioavailability rosuvastatin cmax reached hours administration food affect auc according original sponsor submitted clinical study per product however subsequent clinical study shown marked reduction rosuvastatin exposure administered protein bound mainly fraction absorbed rosuvastatin frequently misquoted literature approximately due miscalculated hepatic extraction ratio original submission package subsequently corrected fda rosuvastatin metabolized mainly extensively metabolized approximately recovered metabolite ndesmethyl rosuvastatin excreted feces primarily elimination halflife approximately rosuvastatin international nonproprietary name low moderate dose statins strongly recommended united states preventive services task force uspstf primary prevention cardiovascular disease adults aged years patient protection affordable care act ppaca united states requires health insurance plans cover costs drugs without charging insured patient copayment coinsurance even yet reached annual rosuvastatin mg mg examples regimens meeting usptfs however insurers discretion low moderatedose statin regimens cover cover drug billed superstatin clinical development claim offers high potency improved cholesterol reduction compared rivals class main competitors rosuvastatin atorvastatin simvastatin however people also combine ezetimibe either simvastatin atorvastatin agents somewhat similar augmented response rates published information comparing rosuvastatin atorvastatin ezetimibesimvastatin results available many relevant studies stillwhen update first launched sales rosuvastatin million million respectively total patient treatment population million end needed annual cost uk national health service nhs mg rosuvastatin daily compared mg fourthhighest selling drug united states accounting approximately billion seventeenth commonly prescribed medication united states million rosuvastatin approved united states treatment high ldl cholesterol dyslipidemia total cholesterol hypercholesterolemia andor triglycerides february rosuvastatin approved fda primary prevention cardiovascular rosuvastatin approved countries launched approval united states food drug administration fda came august main patent protected rosuvastatin expired challenged improper reissue earlier patent challenge rejected thus patent protection continue april fda approved first generic version rosuvastatin watson pharmaceuticals july mylan gained approval generic rosuvastatin october several months introduction europe richard horton editor medical journal lancet criticized way crestor introduced astrazenecas tactics marketing cholesterollowering drug rosuvastatin raise disturbing questions drugs enter clinical practice measures exist protect patients inadequately investigated medicines according editorial lancets editorial position data crestors superiority rely much extrapolation lipid profile data surrogate endpoints little hard clinical endpoints available statins market longer manufacturer responded stating drugs tested successfully many patients correspondence published lancet astrazenecas ceo tom mckillop called editorial flawed incorrect slammed journal making outrageous critique serious wellstudied consumer interest organization public citizen filed citizens petition fda asking crestor withdrawn us market march fda issued letter sidney wolfe public citizen denying petition providing extensive detailed analysis findings demonstrated basis concerns rosuvastatin compared statins approved marketing united wolfe explained thought drug withdrawn used due incidence rhabdomyolysis renal problems significant increase glycated hemoglobin fasting insulin levels decreased insulin sensitivity diabetic patients rosuvastatin indeed lowered cholesterol statins wolfe asked actually improving health preventing heart attacks httpsenwikipediaorgwikirosuvastatin